CClinicalTrials.gg
Status unknownNCT04578522Updated Oct 8, 2020

Correlation Between the Severity of Coronary Artery Disease and Peripheral Arterial Stiffness in Patients With Premature Coronary Heart Disease

An observational study in Premature Coronary Heart Disease, sponsored by Chongqing Medical University. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2020-10-08.

Sponsored by Chongqing Medical University · Observational

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Sex
All
01

Study summary

Premature coronary heart disease (CHD) refers to the onset of myocardial infarction in men \< 55 years old, women \< 65 years old. At present, researches on early-onset coronary heart disease mostly focus on its risk factors and clinical characteristics, but there is no relevant research on the relationship between early-onset myocardial infarction and atherosclerosis.

Read the detailed description

Premature coronary heart disease is defined as the first onset of male \< 55 years old, female \< 65 years old, confirmed by clinical examination. A number of studies have found that smokers have a significantly increased risk of acute myocardial infarction, and suggest that continued smoking is still an independent predictor of mace. These findings suggest that smoking is significantly associated with early-onset coronary heart disease. A number of studies have found that smoking can increase peripheral arterial stiffness. At present, there is no study on peripheral arterial stiffness in patients with early-onset myocardial infarction, so we suspect that peripheral arterial stiffness in patients with early-onset myocardial infarction is significantly increased

02

Conditions studied

  • Premature Coronary Heart Disease

Keywords

  • Premature coronary heart disease
  • Degree of coronary stenosis
  • arterial stiffness
03

In context

Premature Birth

2,553 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's planned enrollment of 200 is above the median of 112 across 777 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Chongqing Medical University is the lead sponsor of 75 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with primary coronary heart disease were male \< 55 years old and female \< 65 years old

Inclusion criteria

  • The onset of coronary heart disease (including acute coronary syndrome and stable angina pectoris) was less than 55 years old in men and 65 years in women

Exclusion criteria

Exclusion Criteria:

  • Non coronary heart disease leading to chest pain (myocarditis, pericarditis, pulmonary embolism, aortic dissection, unstable angina pectoris) definite infection tumor liver and kidney insufficiency autoimmune disease acromegaly hyperthyroidism and subclinical hyperthyroidism secondary hypertension, etc.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Arterial stiffness

    The arterial stiffness of HFpEF patients, for exampleambulatory arterial stiffness indexbrachial ankle pulse wave velocity, ardioankle vascular index and so on.

    Time frame: On admission

  2. Degree of coronary stenosis

    Degree of coronary stenosis indicated by coronary angiography

    Time frame: On admission

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04578522
Lead sponsor
Chongqing Medical University
Responsible party
Dongying Zhang (Clinical Professor, Chongqing Medical University) — Principal investigator
First posted
Oct 8, 2020
Start date
Sep 29, 2020 (estimated)
Primary completion
Sep 29, 2021 (estimated)
Completion
Sep 29, 2021 (estimated)
Last update
Oct 8, 2020

Study contacts

Dongying Zhang, doctor
Contact
zdy.chris@qq.com
+8613608398395
Dongying Zhang, doctor
study director · First Affiliated Hospital of Chongqing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion